This finding was in agreement with the results obtained from network pharmacology; this outcome verified the critical role of NUAK1 in regulating the functionality of CD8+ T cells and its impact on the onset and progression of IPF and that this kinase is a potential therapeutic target for the treatment of IPF. The gene discussed is CD8A; the disease is idiopathic pulmonary fibrosis.